Results 21 to 30 of about 6,652 (162)

Cilostazol for intermittent claudication [PDF]

Cochrane Database of Systematic Reviews, 2014
Peripheral arterial disease (PAD) affects between 4% and 12% of people aged 55 to 70 years, and 20% of people over 70 years. A common complaint is intermittent claudication (exercise-induced lower limb pain relieved by rest). These patients have a three- to six-fold increase in cardiovascular mortality.
Brown, Tamara, Forster, Rachel B, Cleanthis, Marcus, Mikhailidis, Dimitri P, Stansby, Gerard, Stewart, Marlene   +5 more
openaire   +6 more sources

Cilostazol protects hepatocytes against alcohol-induced apoptosis via activation of AMPK pathway.

PLoS ONE, 2019
Alcoholic liver disease (ALD) is a worldwide health problem and hepatocyte apoptosis has been associated with the development/progression of ALD. However, no definite effective pharmacotherapy for ALD is currently available.
Youn Ju Lee, Mi-Sun Shu, Jong-Yeon Kim, Yun-Hye Kim, Kyeong Hwa Sim, Woo Jung Sung, Jong Ryeol Eun   +6 more
doaj   +1 more source

Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC−MS/MS

Journal of Pharmaceutical Analysis, 2015
A simple, rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC−MS/MS) method has been developed for the simultaneous determination of cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in
Nejal M. Bhatt, Vijay D. Chavada, Daxesh P. Patel, Primal Sharma, Mallika Sanyal, Pranav S. Shrivastav   +5 more
doaj   +1 more source

Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives

Journal of Pharmacological Sciences, 2016
Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells.
Toshinori Takagi, Hideaki Hara
doaj   +1 more source

Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing [PDF]

Reviews in Cardiovascular Medicine, 2020
Pacemakers are more commonly recommended than theophylline for sick sinus syndrome (SSS) treatment. The positive effects of cilostazol on bradyarrhythmias also have been reported.
In Tae Jin, Namsik Yoon, Hyung Ki Jeong, Ki Hong Lee, Hyung Wook Park, Jeong Gwan Cho
doaj   +1 more source

The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice. [PDF]

PLoS ONE, 2012
It is important to identify effective contraceptive drugs that cause minimal disruption to physiological processes. Phosphodiesterase 3 (PDE3) inhibitors suppress meiosis in oocytes by decreasing the level of cAMP and blocking the extrusion of the first ...
Min Li, Yang Yu, Jie Yan, Li-Ying Yan, Yue Zhao, Rong Li, Ping Liu, Aaron J Hsueh, Jie Qiao   +8 more
doaj   +1 more source

Validation of the European Society of Cardiology Ischemic and Bleeding Risk Criteria for Risk Stratification After Endovascular Therapy in Japanese Patients With Lower Extremity Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The European Society of Cardiology (ESC) guidelines for peripheral artery disease recommend antithrombotic strategies based on high ischemic risk (HIR) and high bleeding risk (HBR) criteria. However, their prognostic value in patients with lower extremity artery disease (LEAD) undergoing endovascular therapy (EVT) remains unclear ...
Hirokazu Shimono, Daisuke Kanda, Akihiro Tokushige, Nobuhiro Ito, Yutaro Nomoto, Hiroyuki Tabata, Kenta Ohmure, Takuro Kubozono, Mitsuru Ohishi   +8 more
wiley   +1 more source

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model

Scientific Reports
Cilostazol has previously been shown to reduce liver steatosis and enhance hepatic perfusion. We investigated the effects of cilostazol after major hepatectomy in a steatotic rat model. Six weeks prior to surgery, Sprague–Dawley rats were fed with a high-
Sebastian Holländer, Maximilian von Heesen, Gereon Gäbelein, Julie Mercier, Matthias W. Laschke, Michael D. Menger, Matthias Glanemann, Antonios E. Spiliotis   +7 more
doaj   +1 more source

Pretreatment with Cilostazol Attenuates Carboplatin Induced Cytotoxicity and Genotoxicity in Bronchial Epithelial Cells (Beas-2B) and Human Blood Lymphocytes [PDF]

Journal of Mazandaran University of Medical Sciences, 2023
Background and purpose: Cilostazol is a prescription medication for intermittent claudication in patients with peripheral artery disease. Previous research has demonstrated that this 2-oxoquinoline derivative possesses antithrombotic, vasodilator ...
Mohammad Shokrzadeh, Mahboube Rahmati, Elahe Gharehkhani, Rouzbeh Zare, Parsa Pourmohammadi, Shaghayegh Aghajanshakeri   +5 more
doaj  

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source